Company / Total Assets
Viridian Therapeutics, Inc.\DE Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$899.4M
FY2025
5-year range
$203.7M / $899.4M
FY2021-FY2025
Trend
+21.1%
vs FY2024
Sector context
#89 of 214
Health Care
What the data says
At $899M, Viridian Therapeutics, Inc.\DE's total assets ranks #89 of 214 in the Health Care sector. Total Assets has increased for 6 consecutive years, from $30M in FY2019 to $899M in FY2025.
Based on SEC 10-K filings.
$899M in FY2025 with a 5-year CAGR of +46.9%.
Improved from $490M to $899M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +27.4%
- 5-Year CAGR
- +46.9%
- 10-Year CAGR
- -
Sector benchmark
#89 of 214 in Health CareTop 42% of 214This company $899.4M Sector average $7.5B
▼
-88.0% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's total assets has grown for 6 consecutive years.
- 5-year CAGR of +46.9%, indicating consistent growth.
- In FY2025, total assets increased 21.1% year-over-year.
- Ranks #89 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $899.4M | +21.1% |
| FY2024 | $742.4M | +51.4% |
| FY2023 | $490.4M | +12.7% |
| FY2022 | $435.1M | +113.6% |
| FY2021 | $203.7M | +55.2% |
| FY2020 | $131.3M | +333.7% |
| FY2019 | $30.3M | -54.3% |
| FY2018 | $66.1M | +26.0% |
| FY2017 | $52.5M | +112.0% |
| FY2016 | $24.8M | +91.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026